In this study we are looking to characterize changes in bone mineral density (BMD) during continuous treatment with MYFEMBREE®  for up to 4 years in premenopausal women with moderate to severe pain associated with endometriosis.
To qualify, you must:
  • Be a premenopausal woman, 18-50 (inclusive)
  • Patients with endometriosis must have surgical confirmation (by operative report or pathology report) or medical records indicating that the patient has a diagnosis of endometriosis and the investigator attests there is no other explanation for moderate to severe pelvic pain;
  • Be willing to  avoid pregnancy for 4 years (length of study) using a nonhormonal method of contraception
  • Have a BMI of at least 18
  • Not have a contraindication to using MYFEMBREE®
*there are other criteria which must be met to participate
** free study-related medication, study-related exams, bone density testing, mammograms, & labs along with compensation to $1700 for qualified participants
MYFEMBREE®  is currently FDA approved and information can be found here.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.